# Neoadjuvant Inituomab, Pyrrolidone and Nab-paclitaxel for HER2+Breast Cancer

> **NCT05444998** · PHASE2 · UNKNOWN · sponsor: **Xijing Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Intuzumab, pyrrolidone, nab-paclitaxel

## Key facts

- **NCT ID:** NCT05444998
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-01
- **Primary completion:** 2023-08-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05444998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05444998, "Neoadjuvant Inituomab, Pyrrolidone and Nab-paclitaxel for HER2+Breast Cancer". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT05444998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*